Supplemental Table 1 From "Malignancy Rates Through 5 Years of Follow-up in Patients With Moderate-to-Severe Psoriasis Treated With Guselkumab: Pooled Results From the VOYAGE 1 and VOYAGE 2 Trials"

Supplemental Table 1, "Proportion of Guselkumab-Treated Patients With NMSC by Previous use of Psoriasis Therapy," from "Malignancy Rates Through 5 Years of Follow-up in Patients With Moderate-to-Severe Psoriasis Treated With Guselkumab: Pooled Results From the VOYAGE 1 and VOYAGE 2 Trials" accepted for publication in J Am Acad Dermatol March 9, 2023.